Evicenter
Repatha (evolocumab) in Cardiovascular event risk reduction
Manufacturer
Amgen Inc.
Prescribing information
Repatha (opens in a new tab)
Questions
14
Last updated

All questions

Indication: Repatha (evolocumab) in cardiovascular event risk reduction

1 question · 1 source

Indication

What is Repatha approved for in cardiovascular risk reduction?

Note: The indication statement on the Repatha HCP site, as captured on November 13, 2026, omits "or any ischemia-driven arterial revascularization", which the Prescribing Information revised 10/2026 includes; the Prescribing Information is quoted here.